Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Apr 01, 2005 (Vol. 25, No. 7)

NanoInvestorNews Nanotechnology NEMS News

URL:www.nanoinvestornews.com/
  • wealth of information
  • Confusing in places
Starting with the computer boom beginning in the 1980s and continuing with the Internet boom in the 1990s, Wall Street investors have been looking for the “next big thing” in technology to make money on. Biotechnology was hot for a while (and remains in the spotlight), but the buzz for the past couple of years has been nanotechnology. Serving the needs of investors and anyone curious about this emerging area of technology are numerous Websites and printed publications. NanoInvestorNews is one of the latest Web-based information sources, with a focus tilted toward the businessperson. That hopefully won’t scare scientists off, as there is literally something for everyone at the site, including news, patent information, databases, and relevant links to be found.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »